RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Lowers Price Target to $789
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Brian Abrahams has maintained a 'Sector Perform' rating on Regeneron Pharmaceuticals (NASDAQ:REGN) but lowered the price target from $816 to $789.
June 28, 2023 | 1:26 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Regeneron Pharmaceuticals' price target has been lowered from $816 to $789 by RBC Capital, though the 'Sector Perform' rating is maintained.
The lowering of the price target by RBC Capital indicates a potential decrease in the stock's value. However, the maintenance of the 'Sector Perform' rating suggests that the company is expected to perform on par with other companies in the sector, which may mitigate some of the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100